01—Abstract
Summary
Summary of the 8-K filed June 7, 2024. Cited figures are marked; the original filing is the authoritative source.
Becton, Dickinson and Company (BDX) has announced significant financing activities through multiple debt offerings, including €1 billion in 3.828%a Notes due 2032, €800 million in 4.029% Notes due 2036 issued by its subsidiary Becton Dickinson Euro Finance S.à r.l.
(guaranteed by BDX), and $600 millionb in 5.081% Notes due 2029. The primary purpose of these offerings is to fund the cash consideration for the anticipated acquisition of Edwards Lifesciences Corporation's Critical Care business, along with associated fees, expenses, and general corporate purposes. While these offerings are not contingent on the acquisition's completion, their proceeds are earmarked for this strategic move.
02—Key points
Key Highlights
- BDX has raised a total of approximately €1.8 billion and $600 million through separate Euro and USD denominated notes offerings.
- The proceeds from these debt issuances are intended to finance the acquisition of Edwards Lifesciences' Critical Care business.
- The Euro-denominated notes include €1 billion of 3.828% Notes due 2032 (issued by BDX) and €800 million of 4.029% Notes due 2036 (issued by a subsidiary and guaranteed by BDX).
- The USD-denominated notes consist of $600 million of 5.081% Notes due 2029.
- The debt offerings are not conditioned on the consummation of the acquisition, though there is no assurance the acquisition will be completed.
- Specific redemption and default provisions are detailed for each note series, including options for early redemption under certain conditions (e.g., tax law changes, change of control) and mandatory redemption if the acquisition does not proceed.
- The subsidiary's notes carry a special mandatory redemption provision if the acquisition is not completed by a specified date (June 3, 2025, or later agreed date) or if BDX decides not to pursue it.
03—Questions
Frequently Asked Questions
What is the primary reason for these debt offerings?
The primary reason for these debt offerings is to secure funding for the cash consideration required for Becton Dickinson's acquisition of Edwards Lifesciences Corporation's Critical Care business. Additionally, proceeds will cover associated fees, expenses, and general corporate purposes.
Are these debt offerings contingent on the acquisition of the Critical Care business?
No, the debt offerings are not conditioned upon the consummation of the acquisition. However, there is no guarantee that the acquisition itself will be completed.
What are the key terms of the new debt issuances?
BDX issued €1 billion of 3.828% Notes due 2032 and $600 million of 5.081% Notes due 2029. Additionally, a subsidiary issued €800 million of 4.029% Notes due 2036, which are guaranteed by BDX. The interest rates and maturity dates vary across these issuances.
What happens to the proceeds if the acquisition does not go through?
If the acquisition is not consummated by the specified deadline (or if BDX decides not to proceed), there are provisions for special mandatory redemptions of the notes, requiring repurchase at a premium (101% of principal plus accrued interest) under certain circumstances, particularly for the subsidiary's notes.
04—Continue